ArticleBMC pharmacology & toxicology2025
Synergistic potential of Ivermectin and doxorubicin in oral squamous cell carcinoma: an in vitro investigation.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDoxorubicin (DOX) is widely used in cancer therapy, but its role in oral squamous cell carcinoma (OSCC) is limited by resistance and dose-related toxicities. Ivermectin (IVM), an antiparasitic agent with emerging anticancer properties, may enhance DOX efficacy. This study evaluated the effects of IVM alone and in combination with DOX on OSCC cell lines.
methodsIn vitro assays, including MTT viability, apoptosis (Annexin V/PI), cell cycle analysis, RT-qPCR of apoptotic, proliferative, and inflammatory markers, and oxidative stress assays, were performed on HN9 and HEp-2 OSCC cell lines, with OEC as control.
resultsIVM reduced cancer cell viability in a dose-dependent manner and demonstrated a favorable selectivity profile compared to normal cells. Combination treatment with DOX and IVM significantly enhanced cytotoxicity (CI = 0.368, synergistic), induced S-phase cell cycle arrest, and increased apoptosis through upregulation of BAX, Caspase-3, and P53, alongside downregulation of BCL2. The combination also suppressed Ki-67 and IL-6 expression and markedly increased oxidative stress, indicating mitochondrial dysfunction.
conclusionIVM exhibits anticancer activity in OSCC cells and synergistically augments the efficacy of DOX. These findings support the potential of DOX + IVM combination therapy as a novel strategy for OSCC, warranting further validation in in vivo and clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.